Primary Radiotherapy In MEtastatic Lung Cancer

Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.

Trial Details

NCT ID
NCT07135882
Phase
PHASE3
Sponsor
Trans Tasman Radiation Oncology Group
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Radiotherapy followed by chemotherapy
  • Standard of Care (SOC)
Locations (sample)
  • Blacktown, New South Wales, Australia|-33.76667,150.91667
  • Gold Coast, Queensland, Australia|-28.00029,153.43088
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Ballarat, Victoria, Australia|-37.56622,143.84957
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Newly diagnosed metastatic (stage IV) NSCLC, not amenable to curative surgery or curative radiotherapy
  • Histologically or cytologically documented NSCLC
  • Primary suitable for radiotherapy and not requiring immediate palliative thoracic irradiation
  • Investigator deemed appropriate for SoC systemic therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →